CRISPR Therapeutics Unveils Groundbreaking Preclinical Data at AHA Scientific Sessions 2023

CRISPR Therapeutics announced preclinical data at the American Heart Association (AHA) Scientific Sessions 2023, showcasing the potential of their investigational gene editing therapies, CTX310 and CTX320, for the treatment of cardiovascular disease. CTX310 demonstrated durable reductions in angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose, while CTX320 led to durable reductions in lipoprotein(a) (Lp(a)) levels in NHPs. Both therapies were well-tolerated. CTX310 has initiated a clinical trial targeting ANGPTL3, while CTX320 is on track to enter the clinic in the first half of 2024. The data suggest that these therapies have the potential to shift the treatment paradigm for cardiovascular disease towards a potentially one-time, durable therapy.